209 related articles for article (PubMed ID: 18925905)
1. Chronic kidney disease after hematopoietic cell transplantation: a systematic review.
Ellis MJ; Parikh CR; Inrig JK; Kanbay M; Patel UD
Am J Transplant; 2008 Nov; 8(11):2378-90. PubMed ID: 18925905
[TBL] [Abstract][Full Text] [Related]
2. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
3. Late Kidney Morbidity and Mortality in Hematopoietic Cell Transplant Survivors.
Wu NL; Hingorani S; Cushing-Haugen KL; Lee SJ; Chow EJ
Transplant Cell Ther; 2021 May; 27(5):434.e1-434.e6. PubMed ID: 33775588
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.
Ando M; Ohashi K; Akiyama H; Sakamaki H; Morito T; Tsuchiya K; Nitta K
Nephrol Dial Transplant; 2010 Jan; 25(1):278-82. PubMed ID: 19762604
[TBL] [Abstract][Full Text] [Related]
5. Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
Hingorani S; Pao E; Stevenson P; Schoch G; Laskin BL; Gooley T; McDonald GB
Clin J Am Soc Nephrol; 2018 Jun; 13(6):866-873. PubMed ID: 29669818
[TBL] [Abstract][Full Text] [Related]
6. Mini-review of kidney disease following hematopoietic stem cell transplant
.
Sedhom R; Sedhom D; Jaimes E
Clin Nephrol; 2018 Jun; 89(6):389-402. PubMed ID: 29578399
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.
Choi M; Sun CL; Kurian S; Carter A; Francisco L; Forman SJ; Bhatia S
Cancer; 2008 Oct; 113(7):1580-7. PubMed ID: 18704986
[TBL] [Abstract][Full Text] [Related]
8. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic Microangiopathy Increases the Risk of Chronic Kidney Disease but Not Overall Mortality in Long-term Transplant Survivors.
Li A; Gupta R; Amos CI; Davis C; Pao E; Lee SJ; Hingorani SR
Transplant Cell Ther; 2021 Oct; 27(10):864.e1-864.e5. PubMed ID: 34217847
[TBL] [Abstract][Full Text] [Related]
10. Chronic kidney disease after hematopoietic cell transplantation: frequency, risk factors, and outcomes.
Saddadi F; Hakemi M; Najafi I; Moghadam K; Ghavamzadeh A; Jahani M; Ganji M; Amini M; Soleimanian T
Transplant Proc; 2009 Sep; 41(7):2895-7. PubMed ID: 19765466
[TBL] [Abstract][Full Text] [Related]
11. Chronic kidney disease in long-term survivors of hematopoietic cell transplant.
Hingorani S; Guthrie KA; Schoch G; Weiss NS; McDonald GB
Bone Marrow Transplant; 2007 Feb; 39(4):223-9. PubMed ID: 17290279
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation.
Woodahl EL; Hingorani SR; Wang J; Guthrie KA; McDonald GB; Batchelder A; Li M; Schoch HG; McCune JS
Pharmacogenomics J; 2008 Aug; 8(4):248-55. PubMed ID: 17700595
[TBL] [Abstract][Full Text] [Related]
14. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Farhadfar N; Dias A; Wang T; Fretham C; Chhabra S; Murthy HS; Broglie L; D'Souza A; Gadalla SM; Gale RP; Hashmi S; Al-Homsi AS; Hildebrandt GC; Hematti P; Rizzieri D; Chee L; Lazarus HM; Bredeson C; Jaimes EA; Beitinjaneh A; Bashey A; Prestidge T; Krem MM; Marks DI; Benoit S; Yared JA; Nishihori T; Olsson RF; Freytes CO; Stadtmauer E; Savani BN; Sorror ML; Ganguly S; Wingard JR; Pasquini M
Transplant Cell Ther; 2021 May; 27(5):410-422. PubMed ID: 33775617
[TBL] [Abstract][Full Text] [Related]
15. Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute.
Jo T; Arai Y; Kondo T; Kitano T; Hishizawa M; Yamashita K; Takaori-Kondo A
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2159-2165. PubMed ID: 28822830
[TBL] [Abstract][Full Text] [Related]
16. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation.
Weiss AS; Sandmaier BM; Storer B; Storb R; McSweeney PA; Parikh CR
Am J Transplant; 2006 Jan; 6(1):89-94. PubMed ID: 16433761
[TBL] [Abstract][Full Text] [Related]
17. Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function.
Foster GG; Grant MJ; Thomas SM; Cameron B; Raiff D; Corbet K; Loitsch G; Ferreri C; Horwitz M
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1597-1606. PubMed ID: 32450288
[TBL] [Abstract][Full Text] [Related]
18. GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation.
Sakellari I; Barbouti A; Bamichas G; Mallouri D; Kaloyannidis P; Fragidis S; Batsis I; Apostolou C; Karpouza A; Yannaki E; Smias C; Sombolos K; Anagnostopoulos A
Bone Marrow Transplant; 2013 Oct; 48(10):1329-34. PubMed ID: 23584436
[TBL] [Abstract][Full Text] [Related]
19. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
